Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q01718

UPID:
ACTHR_HUMAN

ALTERNATIVE NAMES:
Adrenocorticotropin receptor; Melanocortin receptor 2

ALTERNATIVE UPACC:
Q01718; A8K016; Q3MI45; Q504X6

BACKGROUND:
The Adrenocorticotropic hormone receptor, recognized alternatively as the Melanocortin receptor 2, is integral to the adrenal cortex's cortisol synthesis, responding to ACTH through G(s) protein-mediated activation of adenylate cyclase. This process is vital for maintaining metabolic homeostasis and stress response.

THERAPEUTIC SIGNIFICANCE:
Linked to Glucocorticoid deficiency 1, a life-threatening condition characterized by cortisol production failure, the receptor's study offers a promising avenue for developing targeted therapies that could restore normal adrenal function and prevent the severe consequences of this disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.